Recombinant monoclonal antibodies (rAbs) are synthetic molecules produced in the laboratory to act as specific binding agents to target an antigen. In contrast to conventional monoclonal antibodies produced using hybridoma technology, rAbs are made by recombinant DNA methods, providing higher specificity, scalability, and customizability for applications in therapy and diagnostics. The development of rAbs is one of the major technological milestones in the biotechnology industry, especially for antibody-targeted therapy, diagnostics, and tools for research.
Monoclonal antibodies (mAbs) are homogeneous immunoglobulins that target one epitope on an antigen. Classical mAbs are produced by fusion of B cells from immunized animals with immortalized myeloma cells to form hybridomas that are able to continuously produce antibodies. The process is, however, time-consuming, has limited scalability, and has problems with both reproducibility and animal dependency.
Recombinant monoclonal antibodies break these limitations by employing molecular cloning methods to isolate, transfer, and express antibody genes into host cells like Escherichia coli, yeast, or mammalian cell lines like CHO (Chinese Hamster Ovary) cells. These technologies provide various benefits over antibodies derived from hybridomas, such as sequence-defined products, isotype switch, and humanization.
The process of manufacturing recombinant monoclonal antibodies takes various steps:
Antigen selection and immunization (if necessary): Although certain of the rAbs are from immunized animals, others are generated from naïve or synthetic antibody libraries without the necessity for immunization in vivo.
B-cell or Library Screening: Antibodies are discovered utilizing methods such as phage display, yeast display, or single-cell sequencing of B cells derived from immunized animal or human donors. The method facilitates the selection of binders of required affinity and specificity.
Gene cloning and expression vector design: After identifying appropriate antibody sequences, variable regions are cloned into expression vectors with constant regions of the target isotype. The vectors are frequently optimized to be highly expressed by the chosen host.
Transient or Stable Expression: The host cells are transfected using the recombinant vectors. Transient transfection is utilized for quick expression, whereas stable expression systems are adopted for large-scale, long-duration production.
Purification and Characterization: The rAbs are purified by affinity chromatography through Protein A/G columns and characterized by binding assays, SDS-PAGE, ELISA, SPR, and mass spectrometry to establish identity, purity, as well as functionality.
The switch over to recombinant antibodies has numerous technological as well as operational advantages:
Sequence Definition and Reproducibility: At the amino acid and nucleotide levels, the recombinant antibodies are defined, thereby providing batch-to-batch consistency with complete expression construct control.
Engineering Flexibility: The recombinant format facilitates isotype switching, Fc engineering, as well as the production of bispecific antibodies or antibody fragments (for example, scFv, Fab).
Scalability and Yield: Optimized expression systems that are used with mammalian or microbial hosts enable high-yield production within scalable bioreactors.
Decreased Use of Animals: Phage display technology and synthetic libraries allow the production of antibody candidates without immunization, facilitating the practice of the 3Rs (Replacement, Reduction, Refinement) for animal experimentation.
Humanization and Fully Human Antibodies: The recombinant method facilitates the process of murine antibody humanization and the generation of fully human antibodies through transgenic animals or antibody libraries, diminishing immunogenicity for use in the clinic.
Related: HTP Recombinant Antibody Production in Just 2 Weeks
Recombinant monoclonal antibodies have established themselves as the backbone of contemporary biotherapeutics, with more than 100 licensed antibody drugs and numerous others currently under development. Therapeutic uses encompass:
Oncology: Antibodies targeting tumor-associated antigens such as HER2 (trastuzumab), CD20 (rituximab), and PD-1/PD-L1 (nivolumab, atezolizumab) are standard treatments in cancer immunotherapy.
Autoimmune Diseases: Inflammatory cytokines are neutralized by or blocked by immune checkpoints by Abs such as anti-TNF agents (e.g., adalimumab) across diseases like rheumatoid arthritis and Crohn’s disease.
Infectious Diseases: Monoclonal antibodies have been produced quickly through recombinant methods to target viral proteins (example: SARS-CoV-2 spike protein).
Recombinant antibodies find growing applications in research as well as in diagnostics because of higher specificity and reproducibility over polyclonal antibodies. The applications are as follows:
Flow cytometry and immunohistochemistry (IHC): Sequence-defined antibodies provide consistent signal detection between experiments and between batches.
Western Blotting and ELISA: Recombinant antibodies eliminate cross-reactivity problems frequently observed with animal-derived polyclonals.
Companion diagnostics: Several rAbs are included within diagnostic tests that inform treatment choices, including PD-L1 IHC tests to make tumors eligible for cancer immunotherapy.
rAbs are commonly utilized to investigate the presence, as well as the functionality, of target proteins in drug development pipelines.
Recombinant monoclonal antibodies provide great versatility to design and optimize, allowing for numerous different engineered formats to be tailored toward particular functions:
Chimeric and Humanized Antibodies: Mouse variable regions may be joined to human constant regions to minimize immunogenicity. Humanized antibodies preserve key antigen-binding sites but substitute non-human sequences.
Fc Region Modifications: The engineered Fc domains can be used to regulate effector functions, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and half-life via interactions with the FcRn.
Antibody Fragments: By using recombinant technology, Fab fragments, single-chain variable fragments (scFvs), and nanobodies can be produced to be used where whole antibodies are not preferable.
Bispecific Antibodies: Through recombinant fusion of two distinct variable regions, bispecific antibodies are able to address two targets at once, providing therapeutic opportunity within multifaceted disease pathways.
Antibody-Drug Conjugates (ADCs): Recombinant mAbs are used as selective carriers for cytotoxic agents, enhancing chemotherapy selectivity.
Contract research organizations (CROs) that provide antibody services increasingly use recombinant platforms to fulfill client requests for custom antibodies with known sequences and tailored functionalities. The movement is part of the overall industry migration toward defined, scalable, and reproducible solutions to the development of biologics. Some of the key types of services provided are:
Gene-to-Antibody Pipelines: The end-to-end manufacturing from antigen design and antibody discovery to expression and purification is provided by CROs.
Custom formats and Engineering: Clients regularly ask for antibody formats engineered specifically, including bispecifics, Fc variations, or particular isotypes for preclinical research.
High-throughput screening: The recombinant antibody libraries allow for efficient identification of high-affinity binders to a variety of targets. Codon optimization, humanization, and stability engineering are generally combined into antibody design pipelines.
Expression System Flexibility: Based on project objectives, antibodies can be produced in microbial, insect, or mammalian systems.
At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs, including HTP Recombinant Antibody Production, Bispecific Antibody Production, Large Scale Antibody Production, and Afucosylated Antibody Expression. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
